Clinical trial recovery from COVID 19 disruption
Back to Impact on public health
Journal Article

Clinical trial recovery from COVID 19 disruption

Pharmaceutical industry actions over the next 1–2 years may determine fundamental pivots for how medicines are developed

Since COVID-19 emerged in January 2020, it has caused unprecedented disruption of clinical trials and ongoing patient care. To help understand the recovery from COVID-19 disruption and the implications for the future conduct of clinical trials, we analyzed data from ClinicalTrials.gov and surveyed 245 clinical trial investigators and study coordinators from around the world. Drawing from the results of this in-depth analysis, we present six ongoing challenges ahead—both existing and new--for clinical trials, innovations to address them, and actions to maximize impact.

Clinical trial stakeholders in the pharmaceutical industry can learn more by reading our article, Clinical trial recovery from COVID-19 disruption, published in Nature Reviews Drug Discovery.

Share your feedback and stay connected to the COVID Response Center

The contents of this site, including any statements, articles, graphics, charts, checklists, and other materials (“Content”) are for informational purposes only. The Content is not intended to be a substitute for professional advice or constitute medical advice.